AdvaMed, the Medtech Association, has named Michael “Mick” Farrell, chairman and CEO of Resmed, as its next board of directors chair.
Farrell will serve a two-year term beginning in January 2026. He succeeds Peter Arduini, president and CEO of GE HealthCare (GEHC).
Farrell has served on the company's board since 2015, and currently chairs its International Board Committee. He recently joined an AdvaMed CEO delegation to Japan focused on medtech and healthy aging.
Farrell was appointed CEO of Resmed and joined its board of directors in March 2013. Before Resmed, he held roles at Arthur D. Little, Sanofi Genzyme, and Dow Chemical.
Farrell also serves as lead independent director at Zimmer Biomet, where he is a member of the Compensation and Management Development Committee and the Quality, Regulatory, and Technology Committee.
